Surrogate end points in cardiovascular disease trials

Am Heart J. 2000 Apr;139(4):S193-6. doi: 10.1016/s0002-8703(00)90071-1.
No abstract available

MeSH terms

  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Clinical Trials, Phase II as Topic / statistics & numerical data*
  • Clinical Trials, Phase III as Topic / statistics & numerical data*
  • Data Interpretation, Statistical
  • Humans
  • Reproducibility of Results
  • Survival Analysis